STAT Plus: Kadmon to seek FDA approval of drug targeting graft-versus-host disease following positive study outcome
The New York-based biotech said it intends to submit to the the Food and Drug Administration in October, taking advantage of an agency pilot program.
No hay comentarios:
Publicar un comentario